HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
同型半胱氨酸改变骨基质和矿化
基本信息
- 批准号:7024679
- 负责人:
- 金额:$ 17.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-15 至 2008-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): We hypothesized several years ago that moderate levels of hyperhomocysteinemia may have a causal role in a number of connective tissue pathologies typically thought of as normal consequences of aging. We emphasized the parallels between the hallmark manifestations of homocystinuria (with serum homocysteine concentrations typically >100 (m/L), ie, occlusive vascular disease, osteoporosis, mental deterioration, and ectopia lentis, and the counterpart manifestations of "normal" aging (with serum homocysteine concentrations between 10 and 100 (m/L), ie, occlusive vascular disease, osteoporosis, dementia, and presbyopia. It is important to recognize that these manifestations of elevated homocysteine (Hcy) are generally concentration and age-dependent, i.e., the more severe the hyperhomocysteinemia, the younger the age of onset. For example, osteoporosis is detectable by radiographs in 40% of untreated homocystinuric patients by age 15 and in 80% by age 30. Conversely, moderate hyperhomocysteinemia should require prolonged periods of exposure to produce similar pathology. Thus, with regard to bone, we hypothesize that prolonged, moderately elevatated homocysteine has a causal role in the development of the osteoporosis associated with aging. In this developmental grant we seek funding to establish experimental proof of principle for some of the assumptions underlying our main hypothesis. We HYPOTHESIZE that 1) Hcy- and/or Hcytl-mediated alterations of bone extracellular matrix proteins occur in vivo, and that 2) Hcy and/or Hcytl can impair bone formation by osteoblasts in vitro. To test these hypotheses, we have developed the following respective SPECIFIC AIMS: 1) In this application we seek to isolate proteins from human bone that are modified with Hcy or Hcytl and identify them, if possible. We will examine both cortical and cancellous bone and seek to determine if there is an age-related association between protein-associated Hcy in both types of human bone. In order to better understand the chemistry of this post- translational modification, we will also experiment investigate conditions that result in the incorporation of Hcy into bone matrix proteins. 2) We will establish human bone marrow stromal cell cultures, induce osteoblast differentiation, and evaluate the effects of elevated Hcy and Hcytl on rates of cell proliferation, extracellular matrix formation, extent of osteoblast differentiation and matrix mineralization. We shall also examine the ability of Hcy or Hcytl to alter the extent of mineralization of pre-formed osteoblast-derived matrices. These studies should provide new data regarding possible mechanisms of osteoporosis as well as suggest new therapies for treatment and prevention.
描述(由申请人提供):几年前,我们假设中度高同型半胱氨酸血症可能在许多结缔组织病理学中起因果作用,这些病理学通常被认为是衰老的正常后果。我们强调了同型半胱氨酸尿症的标志性表现(血清同型半胱氨酸浓度通常>100(m/L),即闭塞性血管疾病、骨质疏松症、智力衰退和晶状体异位)与“正常”衰老的对应表现(血清同型半胱氨酸浓度在10和100(m/L)之间,即闭塞性血管疾病、骨质疏松症、痴呆和老花眼)之间的相似性。重要的是要认识到,同型半胱氨酸(Hcy)升高的这些表现通常是浓度和年龄依赖性的,即,高同型半胱氨酸血症越严重,发病年龄越小。例如,在15岁时40%未经治疗的同型胱氨酸尿症患者和30岁时80%未经治疗的同型胱氨酸尿症患者中,可通过X光片检测到骨质疏松症。相反,中度高同型半胱氨酸血症应该需要长时间的暴露才能产生类似的病理。因此,关于骨,我们假设,长期的,中度升高的同型半胱氨酸在与衰老相关的骨质疏松症的发展中具有因果作用。在这个发展补助金,我们寻求资金,以建立实验证明的原则,为我们的主要假设的一些假设。我们假设:1)Hcy和/或Hcytl介导的骨细胞外基质蛋白的改变发生在体内,2)Hcy和/或Hcytl可以损害体外成骨细胞的骨形成。1)在本申请中,我们试图从人骨中分离用Hcy或Hcytl修饰的蛋白质,并在可能的情况下鉴定它们。我们将检查皮质骨和松质骨,并试图确定是否有一个与年龄相关的蛋白质相关的同型半胱氨酸在这两种类型的人骨之间的关联。为了更好地理解这种翻译后修饰的化学性质,我们还将实验研究导致Hcy掺入骨基质蛋白的条件。2)我们将建立人骨髓基质细胞培养,诱导成骨细胞分化,并评估Hcy和Hcytl升高对细胞增殖率,细胞外基质形成,成骨细胞分化程度和基质矿化的影响。我们还将检查Hcy或Hcytl改变预形成的成骨细胞衍生基质的矿化程度的能力。这些研究应该提供有关骨质疏松症可能机制的新数据,并提出新的治疗和预防方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES W PRINCE其他文献
CHARLES W PRINCE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES W PRINCE', 18)}}的其他基金
HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
同型半胱氨酸改变骨基质和矿化
- 批准号:
7229902 - 财政年份:2006
- 资助金额:
$ 17.34万 - 项目类别:
Homocysteine's role in the causation of presbyopia
同型半胱氨酸在老花眼病因中的作用
- 批准号:
6546989 - 财政年份:2002
- 资助金额:
$ 17.34万 - 项目类别:
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
同型半胱氨酸血症——骨质疏松症的危险因素
- 批准号:
3425967 - 财政年份:1993
- 资助金额:
$ 17.34万 - 项目类别:
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
同型半胱氨酸血症——骨质疏松症的危险因素
- 批准号:
2131706 - 财政年份:1993
- 资助金额:
$ 17.34万 - 项目类别:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
骨形成中的蛋白聚糖和骨桥蛋白
- 批准号:
3072205 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
骨形成中的蛋白聚糖和骨桥蛋白
- 批准号:
3072204 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
矿化组织蛋白聚糖的生物化学研究
- 批准号:
3220236 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
BIOCHEMICAL STUDIES OF MINERALIZED TISSUE PROTEOGLYCANS
矿化组织蛋白聚糖的生物化学研究
- 批准号:
2129389 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
骨形成中的蛋白聚糖和骨桥蛋白
- 批准号:
3072207 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
PROTEOGLYCANS AND OSTEOPONTIN IN BONE FORMATION
骨形成中的蛋白聚糖和骨桥蛋白
- 批准号:
3072206 - 财政年份:1988
- 资助金额:
$ 17.34万 - 项目类别:
相似海外基金
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
- 批准号:
10730208 - 财政年份:2023
- 资助金额:
$ 17.34万 - 项目类别:
Impacts of parental benzo[a]pyrene exposure on offspring’s bone development
父母接触苯并[a]芘对后代骨骼发育的影响
- 批准号:
10658133 - 财政年份:2023
- 资助金额:
$ 17.34万 - 项目类别:
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
- 批准号:
10545297 - 财政年份:2022
- 资助金额:
$ 17.34万 - 项目类别:
Tankyrase represses macrophage derived inflammatory cytokines and controls osteoclast activity during bone development.
端锚聚合酶抑制巨噬细胞衍生的炎症细胞因子并控制骨骼发育过程中的破骨细胞活性。
- 批准号:
469104 - 财政年份:2022
- 资助金额:
$ 17.34万 - 项目类别:
Operating Grants
Impacts of parental benzo[a]pyrene exposure on offspring’s bone development
父母接触苯并[a]芘对后代骨骼发育的影响
- 批准号:
10203208 - 财政年份:2021
- 资助金额:
$ 17.34万 - 项目类别:
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
- 批准号:
10353862 - 财政年份:2021
- 资助金额:
$ 17.34万 - 项目类别:
Acid-base regulation during bone development, homeostasis and metabolism
骨骼发育、体内平衡和代谢过程中的酸碱调节
- 批准号:
535680-2019 - 财政年份:2021
- 资助金额:
$ 17.34万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
- 批准号:
10669478 - 财政年份:2021
- 资助金额:
$ 17.34万 - 项目类别:
Quantitative characterization and predictive modeling of cranial bone development in patients with craniosynostosis
颅缝早闭患者颅骨发育的定量特征和预测模型
- 批准号:
10431946 - 财政年份:2020
- 资助金额:
$ 17.34万 - 项目类别:
Acid-base regulation during bone development, homeostasis and metabolism
骨骼发育、体内平衡和代谢过程中的酸碱调节
- 批准号:
535680-2019 - 财政年份:2020
- 资助金额:
$ 17.34万 - 项目类别:
Postgraduate Scholarships - Doctoral